A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: bevacizumab [Avastin]|DRUG: capecitabine [Xeloda]|DRUG: docetaxel
Sponsor: Hoffmann-La Roche